 |
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
|
PRISMEDICAL News
FOR IMMEDIATE RELEASE
Napa, California - May 1, 2001
/PRNewswire/ -- We are pleased to announce that the company's first product has been identified as a requirement in a $5 million Combat Casualty Care Equipment Upgrade Program approved by the U.S. Marine Corp Systems Command. The requirement is identified in an Operation and Maintenance Program Budget for fiscal year 2002. The expected FDA approval in 2001 and recognition of the company's first product as a requirement in a casualty care program support our expectation of product sales as early as 1Q 2002.
In addition, researchers at the Office of Naval Research (ONR) have identified the PRISMEDICAL approach, which eliminates logistical barriers, as a candidate technology that could solve problems associated with moving fluids to the point-of-need for trauma care. The potential to increase medical mobility of life saving fluids would also effect prehospital casualties for mass civilian populations, due to natural disasters and epidemic outbreaks, by allowing "first responders" to provide critical fluid replacement rather than waiting for conventional preparations to be delivered.
Company Overview PRISMEDICAL CORPORATION specializes in the development of disposable devices that produce and deliver therapeutic agents and sterile solutions at the point-of-use. The patented "PRISM" technologies and know-how will provide the healthcare industry with new "point-of-use" platforms that reduce costs inherent in conventional methods and expand the reach of fluid therapies to new patient populations. Our platform technologies will deliver a broad spectrum of fluid therapies, including intravenous administration of therapeutic agents such as drugs, electrolytes and nutrients and various irrigation treatments and dialysis, to significant segments of a $13 billion market.
"PRISM" delivers a broad spectrum of fluid therapies including intravenous administration of therapeutic agents such as drugs, electrolytes and nutrients and various irrigation treatments and dialysis. Our system is comprised of two patented platform technologies: (1) a drug delivery device for a broad spectrum of drug, electrolyte or nutrient therapeutic agents, and a (2) water purification method/device for producing unit-dose volumes of sterile water. Our two platform devices can be used individually or in concert to deliver a broad spectrum of point-of-use fluid therapies.
TOP
Napa, California - May 1, 2001
/PRNewswire/ -- We are pleased to announce that the company's first product has been identified as a requirement in a $5 million Combat Casualty Care Equipment Upgrade Program approved by the U.S. Marine Corp Systems Command. The requirement is identified in an Operation and Maintenance Program Budget for fiscal year 2002. The expected FDA approval in 2001 and recognition of the company's first product as a requirement in a casualty care program support our expectation of product sales as early as 1Q 2002.
In addition, researchers at the Office of Naval Research (ONR) have identified the PRISMEDICAL approach, which eliminates logistical barriers, as a candidate technology that could solve problems associated with moving fluids to the point-of-need for trauma care. The potential to increase medical mobility of life saving fluids would also effect prehospital casualties for mass civilian populations, due to natural disasters and epidemic outbreaks, by allowing "first responders" to provide critical fluid replacement rather than waiting for conventional preparations to be delivered.
Company Overview PRISMEDICAL CORPORATION specializes in the development of disposable devices that produce and deliver therapeutic agents and sterile solutions at the point-of-use. The patented "PRISM" technologies and know-how will provide the healthcare industry with new "point-of-use" platforms that reduce costs inherent in conventional methods and expand the reach of fluid therapies to new patient populations. Our platform technologies will deliver a broad spectrum of fluid therapies, including intravenous administration of therapeutic agents such as drugs, electrolytes and nutrients and various irrigation treatments and dialysis, to significant segments of a $13 billion market.
"PRISM" delivers a broad spectrum of fluid therapies including intravenous administration of therapeutic agents such as drugs, electrolytes and nutrients and various irrigation treatments and dialysis. Our system is comprised of two patented platform technologies: (1) a drug delivery device for a broad spectrum of drug, electrolyte or nutrient therapeutic agents, and a (2) water purification method/device for producing unit-dose volumes of sterile water. Our two platform devices can be used individually or in concert to deliver a broad spectrum of point-of-use fluid therapies.
TOP